CJC/IPA Protocol vs Wolverine Stack
Well Studied vs Well Studied
synergistic Mechanism-based · 47% CJC/IPA Protocol and Wolverine Stack work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC/IPA Protocol Wolverine Stack
Weight N/A N/A
Chain N/A N/A
Type Peptide combination (GHRH analog + GHS) Peptide blend
Key Benefits
CJC/IPA Protocol
01 Sustained GH elevation (6-8 days from CJC-1295)
02 Selective pulsatile release without cortisol suppression
03 Complementary dual-pathway optimization
04 Preservation of natural GH rhythm
05 Enhanced muscle protein synthesis and recovery
Wolverine Stack
01 Complementary healing mechanisms
02 87.5% improvement in knee pain patients
03 Reduced inflammation and enhanced cell migration
04 Promotes angiogenesis and reduces scarring
Dosing Protocols
CJC/IPA Protocol
200-300mcg of each peptide (CJC-1295 and Ipamorelin) / Once daily, preferably in the evening
General Health Optimization 200mcg each (0.2mL if 1mg/mL) Once daily
Performance Enhancement 250mcg each (0.25mL if 1mg/mL) Once daily
Recovery Optimization 300mcg each (0.3mL if 1mg/mL) Once daily
Conservative Approach 150mcg each (0.15mL if 1mg/mL) 5 days per week
Wolverine Stack
BPC-157: 250-500 mcg per dose + TB-500: 2-2.5 mg per dose / BPC-157: 1-2x daily; TB-500: 2x per week (typically Monday/Thursday or Tuesday/Friday)
General Recovery Protocol BPC-157: 250mcg 2x/day + TB-500: 2mg 2x/week BPC-157 daily, TB-500 twice weekly
Intensive Injury Recovery BPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/week BPC-157 daily, TB-500 twice weekly
Maintenance/Prevention Protocol BPC-157: 250mcg 1x/day + TB-500: 2mg 1x/week BPC-157 daily, TB-500 weekly
Side Effects
CJC/IPA Protocol
Water retention and joint swelling
Carpal tunnel syndrome (numbness/tingling)
Mild blood glucose elevation
Injection site irritation with improper rotation
Wolverine Stack
Not extensively documented in human studies
Generally well-tolerated in available research
Contraindications
Cancer history or active malignancy
Severe diabetes requiring tight glucose control
Carpal tunnel syndrome or nerve compression disorders
ANY history of cancer or suspicious growths
Active malignancy or concurrent chemotherapy
Pregnancy or breastfeeding
Research Evidence
CJC/IPA Protocol Wolverine Stack
Status Well Studied Well Studied
References 4 studies 6 studies
Latest June 2024 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.